Key participants in the psoriasis vulgaris industry include Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, and UCB Pharma, in addition to other organizations operating in the psoriasis vulgaris market.
Psoriasis Vulgaris Drug Market Analysis
(Albany, USA) DelveInsight's comprehensive psoriasis vulgaris market analysis report provides a detailed understanding of treatment approaches, epidemiological data, therapies in development, individual treatment market positioning, and current and forecast market size for psoriasis vulgaris across 7MM (US, Germany, France, Italy, Spain, UK, EU5 including Japan) from 2019 to 2032.
The psoriasis vulgaris market research presents the existing treatments, emerging therapeutics, market shares of individual therapies, and the current and forecast assessment of the psoriasis vulgaris market from 2019 to 2032, split into seven major markets. The analysis covers the current treatment protocols/algorithms for psoriasis vulgaris, market catalysts, industry challenges, and unmet medical needs, which will help identify the best opportunities while assessing the potential of the psoriasis vulgaris market.
Request a sample report @Psoriasis Vulgaris Market Outlook
Notable highlights of the Psoriasis Vulgaris market analysis:
- Plaque psoriasis forms a dynamic subcategory within the broader psoriasis indication group, which is projected to reach USD 25.26 billion by 2032, according to DelveInsight analysis.
- DelveInsight researchers note that the market valuation of plaque psoriasis is expected to expand significantly due to the launch of several promising new treatments during the study period.
- Leading pharmaceutical companies treating psoriasis vulgaris include Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics and UCB Pharma, and are positioned to make a major difference in the field of psoriasis vulgaris.
- Emerging treatments for plaque psoriasis expected to be launched during the forecast period include DMB-3115, ducravicitinib, BAT2306, and other therapies.
- According to DelveInsight analysis, approximately 15 million people worldwide suffer from psoriasis, of which approximately 8 million live in the United States and over 6 million in the EU5. Approximately 80% of these patients have plaque psoriasis.
- Despite advances in treatment development over the past decade, patient survey information indicates that moderate to severe plaque psoriasis remains undertreated.
For additional information on the market impact of treatments, please see the Plaque Psoriasis sample.Treatment scenarios for psoriasis vulgaris
Background Information on Psoriasis Vulgaris
Psoriasis vulgaris (also known as plaque psoriasis) is a chronic autoimmune skin disease characterized by red, scaly, inflamed lesions on the scalp, elbows, knees, and lower back. The disease occurs when the immune system mistakenly accelerates skin cell renewal, causing the buildup of excess skin cells.
The exact etiology is still unknown, but genetic factors, immune dysfunction, and environmental factors play important roles. Triggers of plaque psoriasis include stress, infections, certain medications (including beta-blockers, NSAIDs), smoking, alcohol consumption, and cold weather.
Typical symptoms of plaque psoriasis include itchy, burning and cracked skin, which can significantly impact quality of life, and some people may develop psoriatic arthritis, causing joint discomfort and stiffness.
Treatment options for plaque psoriasis range from topical treatments (corticosteroids, vitamin D derivatives), phototherapy, systemic agents (methotrexate, cyclosporine), and biologics targeting inflammatory pathways, such as TNF-α, IL-17, and IL-23 inhibitors.
While there is no definitive cure, lifestyle changes such as moisturizing the skin, reducing stress and avoiding triggers can help control symptoms. Prompt diagnosis and individualized treatment protocols are essential to minimize progression and improve skin health.
In severe cases, biological therapies have transformed treatment approaches, resulting in longer treatment responses and improved patient outcomes. Regular consultations with a dermatologist and/or rheumatologist ensure optimal disease management.
Population Analysis Segmentation of Psoriasis Vulgaris
According to DelveInsight's assessment, psoriasis is the most common inflammatory disease in the United States, affecting up to 8 million Americans, a figure that is expected to grow during the study period.
According to DelveInsight calculations, the total number of diagnosed cases of plaque psoriasis in the U.S. is estimated to exceed 6 million cases in 2021, the highest in the 7MM, and is projected to grow throughout the study period (2019-2032).
Observations suggest that approximately 80-90% of psoriasis patients experience plaque psoriasis, and approximately 20% of psoriasis patients have moderate to severe plaque psoriasis.
The Psoriasis Vulgaris market research provides epidemiological analysis for the study period 2019-2032, 7MM, segmented as follows:
- Total prevalence of psoriasis vulgaris
- Gender-specific prevalence of psoriasis vulgaris
- Psoriasis vulgaris cases by age
- Prevalence of psoriasis vulgaris by severity
Interested in understanding how epidemiological patterns of psoriasis vulgaris will change in the 7MM by 2032? Download herePrevalence of psoriasis vulgaris
Psoriasis Vulgaris Market Outlook
Although plaque psoriasis cannot be cured permanently, treatment of localized plaque psoriasis should begin with patient education and the use of topical corticosteroids with or without coal tar or calcipotriene. Anthralin or tazarotene, alone or in combination with steroids, can then be used after failure of first-line treatment or loss of response to initial treatment. Phototherapy with or without other agents such as psoralens or retinoids may also be required if the disease is difficult to control or widespread.
There are multiple FDA-approved options on the market for the treatment of plaque psoriasis. These include AbbVie's Skyrizi, which received FDA approval in April 2019 for the treatment of moderate to severe plaque psoriasis in adults. Sun Pharma's Ilumya (tildrakizumab-asmn) received FDA approval in March 2018 for the treatment of moderate to severe plaque psoriasis in adults. Johnson & Johnson's plaque psoriasis drug Tremfya (guselkumab) received FDA approval in July 2017. Other FDA-approved and currently available plaque psoriasis drugs include UCB's Cimzia, Eli Lilly's Taltz (ixekizumab), Novartis Pharmaceuticals' Cosentyx (secukinumab), and Amgen's Otezla (apremilast).
The dynamics of the psoriasis vulgaris market is expected to change significantly over the next few years due to intensified research and development activities to bring effective treatment options to the market, including several pipeline therapeutics such as DMB-3115, duclavacitinib, and BAT2306, which are being developed by key psoriasis vulgaris market players Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, and UCB Pharma.
To learn more about a treatment that could capture a significant market share for plaque psoriasis, Psoriasis vulgaris treatment market
Psoriasis Vulgaris Market Forces
DelveInsight researchers predict that the market for plaque psoriasis vulgaris will grow significantly over the next few years, primarily due to the increasing number of cases, recent drug approvals, and the expected launch of new treatments over the forecast period.
Psoriasis Vulgaris Market Growth Factors
- Topical medications can alleviate symptoms but cannot prevent progression or cure the disease, so safer and more effective therapies are needed for the topical treatment of psoriasis vulgaris.
- Expanding global epidemic
- Ongoing research and development activities to identify novel and targeted therapeutics
- Raising awareness levels
Obstacles in the Psoriasis Vulgaris Market
- Poor adherence and compliance
- Entering the generic drug market
- The challenges of managing complex diseases
- Limited awareness
- Huge economic burden
Find out which therapies are predicted to achieve market leadership first.Current status and forecast of psoriasis vulgaris market
Scope of the Psoriasis Vulgaris Market Report
Research period:2019-32
Geographic Coverage:7MM [US, EU5 (Germany, France, Italy, Spain, UK), Japan]
Main organizations for psoriasis vulgaris:AbbVie、Sun Pharma、Johnson & Johnson、UCB、Inc.、Valeant Pharmaceuticals、Eli Lilly and Company、Novartis Pharmaceuticals、Amgen、Meiji Seika Pharma、Soligenix、Dermavant Sciences、Lipidor AB、その他多数。
Main pipeline drugs for psoriasis vulgaris treatment:ME3183, SGX302, Tapinarof, AKP02/AKVANO, and many others.
Treatment evaluation for psoriasis vulgaris:Currently available psoriasis vulgaris medications and new medications
Psoriasis Vulgaris Market Forces:Drivers and obstacles to growth
Strategic Intelligence Analysis:SWOT assessment, PESTLE assessment, Porter's five forces, BCG matrix, market entry approach
Open requirements, expert perspectives, analyst views, access and coverage of psoriasis vulgaris
Report Structure
- Key Insights
- Report Overview
- Overview of the Psoriasis Vulgaris Market
- Overview of Psoriasis Vulgaris
- Population and market analysis of psoriasis vulgaris
- Psoriasis vulgaris: background and overview of the condition
- Diagnosis of psoriasis vulgaris
- Treatment approaches for psoriasis vulgaris
- Conclusion of psoriasis vulgaris
- Population analysis and patient statistics of psoriasis vulgaris
- A psoriasis vulgaris patient's experience
- Primary endpoint of clinical trial for psoriasis vulgaris
- Over-the-counter medications for psoriasis vulgaris
- A new treatment for psoriasis vulgaris
- Psoriasis Vulgaris: Seven Key Market Assessments
- Market Access and Coverage
- Expert Perspective
- Psoriasis Vulgaris Market Growth Factors
- Issues facing the psoriasis vulgaris market
- SWOT assessment of psoriasis vulgaris
- Unsolved requirements for psoriasis vulgaris
- Supplementary Information
- DelveInsight Core Competencies
- Legal disclaimers
- About DelveInsight
About DelveInsight
DelveInsight is a leading life sciences market research and business advisory organization known for its comprehensive syndicated market research studies and customized solutions for companies in the healthcare sector.
Contact Information
Kanishk
kkumar@delveinsight.com
info@delveinsight.com
+14699457679
English
French